“…[17,48] According to Bradley et al, [46] severity assess ment for children aged ≥3 -6 months should also be performed on the grounds of the presence or absence of major and minor risk factors, but this is complex and may require referral. [49] The role of biomarkers in differentiating types of ARTI There is increasing evidence of a role for biomarkers, such as CRP and procalcitonin (PCT), in the management of patients presenting with ARTI. [45] In fact, a recent Cochrane review concluded that POCT for biomarkers (e.g.…”